{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-239512","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2022-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.382167+00:00","generated_at":"2026-06-23T14:32:16.790866+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Candel Therapeutics names new CFO and CMO; CFO Canepa resigns effective Sept 21","bullets":["CFO John Canepa resigned effective Sept 21, 2022, to pursue other interests.","Jason Amello appointed CFO effective Sept 21, 2022; base salary $460K, target bonus 40%.","Garrett Nichols, MD, MS, appointed CMO effective Sept 12, 2022.","Amello brings experience from Saniona, Akebia, Genzyme; Nichols from Istari, GSK."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-239512","json":"https://secwatch.observer/filing/0001193125-22-239512.json","markdown":"https://secwatch.observer/filing/0001193125-22-239512.md","text":"https://secwatch.observer/filing/0001193125-22-239512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000119312522239512/0001193125-22-239512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000119312522239512/d352591d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T14:32:16.790866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4af30012bc","claim":"John Canepa resigned as Chief Financial Officer at Candel Therapeutics, Inc..","evidence_excerpt":"On September 6, 2022, Candel Therapeutics, Inc. (the “Company”) accepted the resignation of John Canepa as the Company’s Chief Financial Officer, effective September 21, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312522239512/0001193125-22-239512-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"4e9e10f3fe","claim":"Jason Amello was appointed as Chief Financial Officer at Candel Therapeutics, Inc..","evidence_excerpt":"Jason Amello as the Company’s Chief Financial Officer, effective September 21, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312522239512/0001193125-22-239512-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"903513569e","claim":"Garrett Nichols was appointed as Chief Medical Officer at Candel Therapeutics, Inc..","evidence_excerpt":"appointed Garrett Nichols. M.D., M.S., as the Company’s Chief Medical Officer, effective September 12, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312522239512/0001193125-22-239512-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}